Sanofi, GSK to seek regulatory approval for Covid vaccine candidate

Sanofi-GSK's shot relies on a conventional protein-based approach, compared with the newer mRNA technology used in established Covid-19 vaccines from Pfizer-BioNTech and Moderna

French drugmaker Sanofi and its British partner GlaxoSmithKline are seeking regulatory approval for their Covid-19 vaccine to be used as a booster, as well as a standalone two-dose shot, after several setbacks.

The companies said on Wednesday they intended to submit data to regulators from a late-stage trial of the vaccine, and another testing it as a booster, with full results for both studies expected to be published "later this year." Sanofi, which plans to produce the vaccine in France, Italy and the United Sates, is hoping for a comeback after falling behind in the race for Covid-19 shots, while GSK,